Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 121 - 140 results of 77,517 for search '(( 2 e decrease ) OR ( 5 ((((mean decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.12s Refine Results
  1. 121
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 122
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 123
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 124
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 125
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 126
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 127
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 128
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 129
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 130
    Klf5 down-regulation leads to human VSMC senescence.

    Klf5 down-regulation leads to human VSMC senescence. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  11. 131
    Knockdown of Ube2d proteins decreases ubiquitination of EGFR in HeLa cells.

    Knockdown of Ube2d proteins decreases ubiquitination of EGFR in HeLa cells. by Mariya S. Liyasova (3821908)

    Published 2019
    Save to List
    Saved in:
  12. 132
    Colony survival is decreased in 2'-O-ribose <i>trm</i> mutants after exposure to oxidative stress-inducing agents.

    Colony survival is decreased in 2'-O-ribose <i>trm</i> mutants after exposure to oxidative stress-inducing agents. by Lauren Endres (765718)

    Published 2020
    Save to List
    Saved in:
  13. 133
    Klf5 expression is down-regulated in the ruptured human and experimental AAA.

    Klf5 expression is down-regulated in the ruptured human and experimental AAA. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  14. 134
    Klf5 deficiency in mouse VSMCs leads to mitochondrial fission.

    Klf5 deficiency in mouse VSMCs leads to mitochondrial fission. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  15. 135
    Mitochondrial morphology assay.

    Mitochondrial morphology assay. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  16. 136
    Analysis of relative fluorescence intensity.

    Analysis of relative fluorescence intensity. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  17. 137
    ATP assay.

    ATP assay. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  18. 138
    The expression of eIF5a, Fis1, Pink1, Drp1, Mfn1, and Mtfr1 and the analysis of mitochondrial morphology.

    The expression of eIF5a, Fis1, Pink1, Drp1, Mfn1, and Mtfr1 and the analysis of mitochondrial morphology. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  19. 139
    The correlation of the mitochondrial dynamics–related genes with Klf5 in mouse VSMCs.

    The correlation of the mitochondrial dynamics–related genes with Klf5 in mouse VSMCs. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  20. 140
    CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA.

    CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA. by Wanassa Beroual (5314028)

    Published 2022
    Save to List
    Saved in:

Search Tools: